Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS)

Shalini L. Kulasingam, Jane J. Kim, William F. Lawrence, Jeanne S. Mandelblatt, Evan R. Myers, Mark Schiffman, Diane Solomon, Sue J. Goldie, E. E. Partridge, L. Kilgore, S. Hester, J. L. Walker, G. A. Johnson, A. Yadack, R. S. Guido, K. McIntyre-Seltman, R. P. Edwards, J. Gruss, N. B. Kiviat, L. KoutskyC. Mao, Daron Gale Ferris, J. T. Cox, L. Burke, C. M. Wheeler, C. Peyton-Goodall, M. M. Manos, R. J. Kurman, D. L. Rosenthal, M. E. Sherman, M. H. Stoler, D. M. Harper, J. Rosenthal, M. Dunn, J. Quarantillo, D. Robinson, A. Lorincz, B. Kramer

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations. Methods: Data from the ALTS trial were used in conjunction with medical care costs in a short-term decision model. The model compared the incremental costs per case of CIN3+ detected as measured by the incremental cost-effectiveness ratio (ICER) for the following management strategies for women with ASCUS: immediate colposcopy, HPV DNA testing, and conservative management with up to three cytology examinations. Results: The least costly and least sensitive strategy was conservative management with one repeat cytology examination using a threshold of high-grade squamous intraepithelial lesion (HSIL) for referral to colposcopy. Compared with this strategy, triage to colposcopy based on a positive HPV DNA test result had an ICER of $3517 per case of CIN3+ detected. Immediate colposcopy and conservative management with up to three repeat cytology visits detected fewer cases of CIN3+ and were more costly than HPV DNA testing. Immediate colposcopy became cost-effective at $20 370 compared with HPV DNA testing only if colposcopy and biopsy were assumed to be 100% sensitive. Conclusions: HPV DNA testing is an economically viable strategy for triage of ASCUS cytology. The less than perfect sensitivity of colposcopy and biopsy needs to be accounted for in future clinical guidelines and policy analyses.

Original languageEnglish (US)
Pages (from-to)92-100
Number of pages9
JournalJournal of the National Cancer Institute
Volume98
Issue number2
DOIs
StatePublished - Jan 18 2006

Fingerprint

Colposcopy
Triage
Cost-Benefit Analysis
Cell Biology
DNA
Costs and Cost Analysis
Human Papillomavirus DNA Tests
Referral and Consultation
Squamous Intraepithelial Lesions of the Cervix
Atypical Squamous Cells of the Cervix
Biopsy
Cervical Intraepithelial Neoplasia
Policy Making
Health Care Costs
Guidelines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). / Kulasingam, Shalini L.; Kim, Jane J.; Lawrence, William F.; Mandelblatt, Jeanne S.; Myers, Evan R.; Schiffman, Mark; Solomon, Diane; Goldie, Sue J.; Partridge, E. E.; Kilgore, L.; Hester, S.; Walker, J. L.; Johnson, G. A.; Yadack, A.; Guido, R. S.; McIntyre-Seltman, K.; Edwards, R. P.; Gruss, J.; Kiviat, N. B.; Koutsky, L.; Mao, C.; Ferris, Daron Gale; Cox, J. T.; Burke, L.; Wheeler, C. M.; Peyton-Goodall, C.; Manos, M. M.; Kurman, R. J.; Rosenthal, D. L.; Sherman, M. E.; Stoler, M. H.; Harper, D. M.; Rosenthal, J.; Dunn, M.; Quarantillo, J.; Robinson, D.; Lorincz, A.; Kramer, B.

In: Journal of the National Cancer Institute, Vol. 98, No. 2, 18.01.2006, p. 92-100.

Research output: Contribution to journalArticle

Kulasingam, SL, Kim, JJ, Lawrence, WF, Mandelblatt, JS, Myers, ER, Schiffman, M, Solomon, D, Goldie, SJ, Partridge, EE, Kilgore, L, Hester, S, Walker, JL, Johnson, GA, Yadack, A, Guido, RS, McIntyre-Seltman, K, Edwards, RP, Gruss, J, Kiviat, NB, Koutsky, L, Mao, C, Ferris, DG, Cox, JT, Burke, L, Wheeler, CM, Peyton-Goodall, C, Manos, MM, Kurman, RJ, Rosenthal, DL, Sherman, ME, Stoler, MH, Harper, DM, Rosenthal, J, Dunn, M, Quarantillo, J, Robinson, D, Lorincz, A & Kramer, B 2006, 'Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS)', Journal of the National Cancer Institute, vol. 98, no. 2, pp. 92-100. https://doi.org/10.1093/jnci/djj009
Kulasingam, Shalini L. ; Kim, Jane J. ; Lawrence, William F. ; Mandelblatt, Jeanne S. ; Myers, Evan R. ; Schiffman, Mark ; Solomon, Diane ; Goldie, Sue J. ; Partridge, E. E. ; Kilgore, L. ; Hester, S. ; Walker, J. L. ; Johnson, G. A. ; Yadack, A. ; Guido, R. S. ; McIntyre-Seltman, K. ; Edwards, R. P. ; Gruss, J. ; Kiviat, N. B. ; Koutsky, L. ; Mao, C. ; Ferris, Daron Gale ; Cox, J. T. ; Burke, L. ; Wheeler, C. M. ; Peyton-Goodall, C. ; Manos, M. M. ; Kurman, R. J. ; Rosenthal, D. L. ; Sherman, M. E. ; Stoler, M. H. ; Harper, D. M. ; Rosenthal, J. ; Dunn, M. ; Quarantillo, J. ; Robinson, D. ; Lorincz, A. ; Kramer, B. / Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). In: Journal of the National Cancer Institute. 2006 ; Vol. 98, No. 2. pp. 92-100.
@article{6d17b93fac184db0b4d5145087f8aabd,
title = "Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS)",
abstract = "Background: The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations. Methods: Data from the ALTS trial were used in conjunction with medical care costs in a short-term decision model. The model compared the incremental costs per case of CIN3+ detected as measured by the incremental cost-effectiveness ratio (ICER) for the following management strategies for women with ASCUS: immediate colposcopy, HPV DNA testing, and conservative management with up to three cytology examinations. Results: The least costly and least sensitive strategy was conservative management with one repeat cytology examination using a threshold of high-grade squamous intraepithelial lesion (HSIL) for referral to colposcopy. Compared with this strategy, triage to colposcopy based on a positive HPV DNA test result had an ICER of $3517 per case of CIN3+ detected. Immediate colposcopy and conservative management with up to three repeat cytology visits detected fewer cases of CIN3+ and were more costly than HPV DNA testing. Immediate colposcopy became cost-effective at $20 370 compared with HPV DNA testing only if colposcopy and biopsy were assumed to be 100{\%} sensitive. Conclusions: HPV DNA testing is an economically viable strategy for triage of ASCUS cytology. The less than perfect sensitivity of colposcopy and biopsy needs to be accounted for in future clinical guidelines and policy analyses.",
author = "Kulasingam, {Shalini L.} and Kim, {Jane J.} and Lawrence, {William F.} and Mandelblatt, {Jeanne S.} and Myers, {Evan R.} and Mark Schiffman and Diane Solomon and Goldie, {Sue J.} and Partridge, {E. E.} and L. Kilgore and S. Hester and Walker, {J. L.} and Johnson, {G. A.} and A. Yadack and Guido, {R. S.} and K. McIntyre-Seltman and Edwards, {R. P.} and J. Gruss and Kiviat, {N. B.} and L. Koutsky and C. Mao and Ferris, {Daron Gale} and Cox, {J. T.} and L. Burke and Wheeler, {C. M.} and C. Peyton-Goodall and Manos, {M. M.} and Kurman, {R. J.} and Rosenthal, {D. L.} and Sherman, {M. E.} and Stoler, {M. H.} and Harper, {D. M.} and J. Rosenthal and M. Dunn and J. Quarantillo and D. Robinson and A. Lorincz and B. Kramer",
year = "2006",
month = "1",
day = "18",
doi = "10.1093/jnci/djj009",
language = "English (US)",
volume = "98",
pages = "92--100",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS)

AU - Kulasingam, Shalini L.

AU - Kim, Jane J.

AU - Lawrence, William F.

AU - Mandelblatt, Jeanne S.

AU - Myers, Evan R.

AU - Schiffman, Mark

AU - Solomon, Diane

AU - Goldie, Sue J.

AU - Partridge, E. E.

AU - Kilgore, L.

AU - Hester, S.

AU - Walker, J. L.

AU - Johnson, G. A.

AU - Yadack, A.

AU - Guido, R. S.

AU - McIntyre-Seltman, K.

AU - Edwards, R. P.

AU - Gruss, J.

AU - Kiviat, N. B.

AU - Koutsky, L.

AU - Mao, C.

AU - Ferris, Daron Gale

AU - Cox, J. T.

AU - Burke, L.

AU - Wheeler, C. M.

AU - Peyton-Goodall, C.

AU - Manos, M. M.

AU - Kurman, R. J.

AU - Rosenthal, D. L.

AU - Sherman, M. E.

AU - Stoler, M. H.

AU - Harper, D. M.

AU - Rosenthal, J.

AU - Dunn, M.

AU - Quarantillo, J.

AU - Robinson, D.

AU - Lorincz, A.

AU - Kramer, B.

PY - 2006/1/18

Y1 - 2006/1/18

N2 - Background: The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations. Methods: Data from the ALTS trial were used in conjunction with medical care costs in a short-term decision model. The model compared the incremental costs per case of CIN3+ detected as measured by the incremental cost-effectiveness ratio (ICER) for the following management strategies for women with ASCUS: immediate colposcopy, HPV DNA testing, and conservative management with up to three cytology examinations. Results: The least costly and least sensitive strategy was conservative management with one repeat cytology examination using a threshold of high-grade squamous intraepithelial lesion (HSIL) for referral to colposcopy. Compared with this strategy, triage to colposcopy based on a positive HPV DNA test result had an ICER of $3517 per case of CIN3+ detected. Immediate colposcopy and conservative management with up to three repeat cytology visits detected fewer cases of CIN3+ and were more costly than HPV DNA testing. Immediate colposcopy became cost-effective at $20 370 compared with HPV DNA testing only if colposcopy and biopsy were assumed to be 100% sensitive. Conclusions: HPV DNA testing is an economically viable strategy for triage of ASCUS cytology. The less than perfect sensitivity of colposcopy and biopsy needs to be accounted for in future clinical guidelines and policy analyses.

AB - Background: The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations. Methods: Data from the ALTS trial were used in conjunction with medical care costs in a short-term decision model. The model compared the incremental costs per case of CIN3+ detected as measured by the incremental cost-effectiveness ratio (ICER) for the following management strategies for women with ASCUS: immediate colposcopy, HPV DNA testing, and conservative management with up to three cytology examinations. Results: The least costly and least sensitive strategy was conservative management with one repeat cytology examination using a threshold of high-grade squamous intraepithelial lesion (HSIL) for referral to colposcopy. Compared with this strategy, triage to colposcopy based on a positive HPV DNA test result had an ICER of $3517 per case of CIN3+ detected. Immediate colposcopy and conservative management with up to three repeat cytology visits detected fewer cases of CIN3+ and were more costly than HPV DNA testing. Immediate colposcopy became cost-effective at $20 370 compared with HPV DNA testing only if colposcopy and biopsy were assumed to be 100% sensitive. Conclusions: HPV DNA testing is an economically viable strategy for triage of ASCUS cytology. The less than perfect sensitivity of colposcopy and biopsy needs to be accounted for in future clinical guidelines and policy analyses.

UR - http://www.scopus.com/inward/record.url?scp=31544476536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544476536&partnerID=8YFLogxK

U2 - 10.1093/jnci/djj009

DO - 10.1093/jnci/djj009

M3 - Article

C2 - 16418511

AN - SCOPUS:31544476536

VL - 98

SP - 92

EP - 100

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -